Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Natura:	Artigo
Lingua:	inglese
Pubblicazione:	2011
Accesso online:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Predicting the outcome of ankylosing spondylitis therapy
di: Vastesaeger, Nathan, et al.
Pubblicazione: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
di: Bert Vander Cruyssen, et al.
Pubblicazione: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
di: van der Heijde, Désirée, et al.
Pubblicazione: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
di: Désirée van der Heijde, et al.
Pubblicazione: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
di: Braun, Jürgen, et al.
Pubblicazione: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
di: Jürgen Braun, et al.
Pubblicazione: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
di: Wagner, Carrie, et al.
Pubblicazione: (2011)

Ankylosing spondylitis: an overview
di: Joachim Sieper, et al.
Pubblicazione: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
di: Deodhar, Atul, et al.
Pubblicazione: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
di: Atul Deodhar, et al.
Pubblicazione: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
di: Braun, J, et al.
Pubblicazione: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
di: Désirée van der Heijde, et al.
Pubblicazione: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
di: Dominique Baeten, et al.
Pubblicazione: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
di: Jürgen Braun, et al.
Pubblicazione: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
di: Jürgen Braun, et al.
Pubblicazione: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
di: Jürgen Braun, et al.
Pubblicazione: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
di: Inman, Robert D., et al.
Pubblicazione: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
di: Xenofon Baraliakos, et al.
Pubblicazione: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
di: Braun, Jürgen, et al.
Pubblicazione: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
di: Jürgen Braun, et al.
Pubblicazione: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
di: Cruyssen, Bert Vander, et al.
Pubblicazione: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
di: Bert Vander Cruyssen, et al.
Pubblicazione: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
di: Annelies Boonen, et al.
Pubblicazione: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
di: Braun, Jürgen, et al.
Pubblicazione: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
di: Sambrook, Philip N., et al.
Pubblicazione: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
di: Philip N. Sambrook, et al.
Pubblicazione: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
di: Braun, Jürgen, et al.
Pubblicazione: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
di: Zochling, J, et al.
Pubblicazione: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
di: Désirée van der Heijde, et al.
Pubblicazione: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
di: Ben A. C. Dijkmans, et al.
Pubblicazione: (2009)

Ankylosing spondylitis: an overview
di: Sieper, J, et al.
Pubblicazione: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
di: Sudha Visvanathan, et al.
Pubblicazione: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
di: Braun, J, et al.
Pubblicazione: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
di: Jürgen Braun, et al.
Pubblicazione: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
di: Davis, J C, et al.
Pubblicazione: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
di: Désirée van der Heijde, et al.
Pubblicazione: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
di: Braun, J, et al.
Pubblicazione: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
di: Désirée van der Heijde, et al.
Pubblicazione: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
di: Vosse, D, et al.
Pubblicazione: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
di: Jürgen Braun, et al.
Pubblicazione: (2016)